Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) secured critical regulatory alignment with the U.S. Food and Drug Administration (FDA) for its lead asset, ATH434, establishing a clear pathway for approval in Multiple System Atrophy (MSA). The biotechnology company confirmed that the FDA agreed a single pivotal Phase 3 trial, supplemented by confirmatory evidence from its earlier Phase 2 data, could support a New Drug Application (NDA). This development de-risks the regulatory trajectory for what could become the first disease-modifying treatment for MSA, a rare neurodegenerative condition with no current approved therapy. The company aims to initiate Phase 3 trial activities by year-end 2026.

David Stamler, M.D., Chief Executive Officer, stated that the positive End-of-Phase 2 meeting outcome provides the regulatory clarity necessary to execute on Phase 3 plans. The alignment covers key trial design elements, including the study population, treatment regimen, and the use of the 11-item UMSARS Part I rating scale as the primary endpoint. The proposed study will enroll approximately 200 patients randomized 1:1 to receive either ATH434 50 mg or a matching placebo twice daily for 12 months. Alterity also plans to offer an open-label extension to participants completing the trial to enhance the safety database.

Financial Position and Cash Flow

As of June 30, 2026, Alterity held cash and cash equivalents totaling A$37.3 million. Operating cash outflows for the quarter amounted to A$7.72 million. Subsequent to the quarter-end, on July 9, 2026, the company received an Australian R&D Tax Incentive refund for the 2025 financial year totaling A$3,982,992, which included A$43,117 in interest. This inflow supports the continued development of its clinical programs.

In accordance with ASX Listing Rule 4.7C, related party payments during the quarter totaled A$309,000. These payments covered non-executive directors’ fees, managing director salary, consulting fees, remuneration, and superannuation at commercial rates.

Strategic and Corporate Developments

Alterity is actively evaluating strategic funding and partnering alternatives to support the advancement of ATH434. The company is engaging with pharmaceutical companies and utilizing external advisers to assess opportunities that maximize long-term shareholder value. On the corporate governance front, Alterity appointed Ann Cunningham as an independent Non-Executive Director in April 2026, adding global commercial expertise to the Board of Directors.

The company also completed a share consolidation on a 1-for-50 basis following shareholder approval at its Extraordinary General Meeting held on May 29, 2026. Scientifically, Alterity continued to disseminate clinical data through presentations at major congresses, including the American Academy of Neurology Annual Meeting and the International Society for Magnetic Resonance in Medicine. A peer-reviewed publication in NeuroImage further validated quantitative susceptibility mapping of brain iron as a biomarker for MSA.

What the Numbers Show

The receipt of the A$3.98 million tax refund shortly after the quarter-end significantly bolsters Alterity’s liquidity position ahead of capital-intensive Phase 3 activities. With operating outflows of A$7.72 million in Q4 FY26, the company’s burn rate suggests the need for efficient capital deployment. The successful manufacturing of the first registration batch of ATH434 indicates operational readiness, while the ongoing evaluation of partnership options highlights the strategic imperative to secure additional funding or co-development support to sustain the program through pivotal trials.

Alterity Therapeutics Limited announced that Chief Executive Officer David Stamler will participate in the virtual BTIG Biotechnology Conference 2026 scheduled for July 28-29, 2026. Dr. Stamler will conduct 1-on-1 meetings with investors based in the United States to discuss the company's developments.

Company Overview

Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease modifying therapies for neurodegenerative diseases. The company's primary targets include Multiple System Atrophy (MSA) and related Parkinsonian disorders.

Clinical Pipeline

The company is preparing to initiate a Phase 3 pivotal trial for MSA, a rare and rapidly progressive disease. Its lead asset, ATH434, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial. Additionally, Alterity has reported positive data from an open label Phase 2 clinical trial involving participants with advanced MSA.

Research Platform

Alterity Therapeutics maintains a broad drug discovery platform designed to generate patentable chemical compounds aimed at treating the underlying pathology of neurological diseases. The company operates from Melbourne, Australia, and San Francisco, California, USA.